Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs

NEXT STORY
FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
PREV STORY
RTI Surgical® Completes Acquisition of Paradigm Spine
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH

author_avatar
NASDAQ Market News

CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING

author_avatar
NASDAQ Market News

Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin

Additional data and analyses from STRIVE Phase 2 clinical trial confirm positive efficacy results in ...

author_avatar
NASDAQ Market News